Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bril

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Journal of the Endocrine Society|January 1, 2026
Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance AssessmentAnu Sharma, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.
Annals of Internal Medicine|June 21, 2016
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized TrialKenneth Cusi, Beverly Orsak, Fernando Bril, et al.
Diabetes Care|October 13, 2019
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 DiabetesFernando Bril, Michael J McPhaul, Michael P Caulfield, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|October 13, 2018
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitusFernando Bril, Michael J McPhaul, Michael P Caulfield, et al.
Journal of Hepatology|August 27, 2013
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver diseaseKenneth Cusi, Zhi Chang, Steve Harrison, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
The International Journal of Risk & Safety in Medicine|September 20, 2013
Adverse drug reactions as a reason for admission to an internal medicine ward in ArgentinaPaulino A Alvarez, Fernando Bril, Verónica Castro, et al.
Current Drug Safety|May 20, 2016
A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant PatientsFernando Bril, Veronica Castro, Ignacio G Centurion, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 11, 2018
Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitisSrilaxmi Kalavalapalli, Fernando Bril, Jeremy P Koelmel, et al.
The Journal of Clinical Endocrinology and Metabolism|December 18, 2015
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLDFernando Bril, John J Sninsky, Arthur M Baca, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Journal of the Endocrine Society|January 1, 2026
Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance AssessmentAnu Sharma, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.
Annals of Internal Medicine|June 21, 2016
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized TrialKenneth Cusi, Beverly Orsak, Fernando Bril, et al.
Diabetes Care|October 13, 2019
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 DiabetesFernando Bril, Michael J McPhaul, Michael P Caulfield, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|October 13, 2018
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitusFernando Bril, Michael J McPhaul, Michael P Caulfield, et al.
Journal of Hepatology|August 27, 2013
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver diseaseKenneth Cusi, Zhi Chang, Steve Harrison, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
The International Journal of Risk & Safety in Medicine|September 20, 2013
Adverse drug reactions as a reason for admission to an internal medicine ward in ArgentinaPaulino A Alvarez, Fernando Bril, Verónica Castro, et al.
Current Drug Safety|May 20, 2016
A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant PatientsFernando Bril, Veronica Castro, Ignacio G Centurion, et al.
American Journal of Physiology. Endocrinology and Metabolism|April 11, 2018
Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitisSrilaxmi Kalavalapalli, Fernando Bril, Jeremy P Koelmel, et al.
The Journal of Clinical Endocrinology and Metabolism|December 18, 2015
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLDFernando Bril, John J Sninsky, Arthur M Baca, et al.
Pageof 11